Nanopublication

ID

http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA
Formats

Content

@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix this: <http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA> .
@prefix sub: <http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_3393> biolink:category biolink:Disease .
  
  sub:association a rdf:Statement;
    rdf:object <http://purl.obolibrary.org/obo/DOID_3393>;
    rdf:predicate biolink:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00669>;
    rdfs:label "\"Sumatriptan succinate tablets are contraindicated in patients with:   Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina  [see Warnings and Precautions ( )]  5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders  [see Warnings and Precautions ( )]  5.2 History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke ee  [s Warnings and Precautions ( )]  5.4 Peripheral vascular disease  [see Warnings and Precautions ( )]  5.5 Ischemic bowel disease  [see Warnings and Precautions ( )]  5.5 Uncontrolled hypertension  [see Warnings and Precautions ( )]  5.8 Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT ) agonist  1 [see Drug Interactions ( , )]  7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor  [see Drug Interactions ( ) and Clinical Pharmacology ( )]  7.2 12.3 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen)  [see Warnings and Precautions ( )]  5.9 Severe hepatic impairment  [see Use in Specific Populations ( ) and Clinical Pharmacology ( )]  8.6 12.3   History of coronary artery disease or coronary artery vasospasm ( )  4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( )  4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( )  4 Peripheral vascular disease ( )  4 Ischemic bowel disease ( ) Uncontrolled hypertension ( )  4 4 Recent (within 24 hours) use of another 5-HT agonist (e.g., another triptan) or of an ergotamine-containing medication. ( )  1 4 Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor. ( )  4 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen). ( )  4 Severe hepatic impairment. ( )  4\"";
    biolink:provided_by <https://w3id.org/um/NeuroDKG>;
    biolink:relation schema:MedicalContraindication .
  
  <https://identifiers.org/drugbank:DB00669> biolink:category biolink:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "ZAh6oE0xACbDNCRg2RfWCvcnyRv+XJ9vzKh/Z8eznwTvZCjS7JXJFpAEP8A7ODePRriXLqV/Zc6upMDwsM7tzbxbRvgW27IYpx3wVCiFAGnHpDPclL+rLI7CV86NUegqbA1UQUlQ0kyir50Al2MdibYTLgPbalvzxw4fcFWdnYs=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-08-23T13:06:35.109+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    ns1:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    ns1:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}